SARS-CoV-2, the human placenta, and adverse perinatal outcomes

- 2 Rebecca L. LINN, MD,¹ Markolline FORKPA, MPH,² Rita LEITE, MD,² Jessenia C.
- 3 GUERRERO, MD, Maria C. REYES, MD, Lauren E. SCHWARTZ, MD, Rebecca A.
- 4 SIMMONS, MD,⁴ Samuel PARRY, MD,² Thea N. GOLDEN, PharmD, PhD;² Philadelphia, PA
- ¹Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia
- ²Department of Obstetrics and Gynecology, Perelman School of Medicine at the University of
- 7 Pennsylvania

1

11

15

- 8 ³Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the
- 9 University of Pennsylvania
- ⁴Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
- 12 **Disclosure statement:** The authors do not have commercial associations that might pose
- conflicts of interest, such as ownership, stock holdings, equity interests and consultant activities,
- or patent-licensing situations.
- 16 Sources of funding: This work was funded by a COVID-19 grant from the March of Dimes
- 17 (Parry and Simmons) and two mentored scientist awards from the University of Pennsylvania
- 18 (Golden, ES019851 Translational Research Training Program in Environmental Sciences and
- 19 ES013508 Mentored Scientist Transition Award funded by the Center for Excellence in
- 20 Environmental Toxicology). The sponsors did not participate in study design; in the collection,
- analysis and interpretation of data; in the writing of this report; and in the decision to submit this
- 22 manuscript for publication.
- 24 Corresponding author:
- 25 Samuel Parry, MD
- 26 Franklin Payne Professor, Department of Obstetrics and Gynecology

Perelman School of Medicine at the University of Pennsylvania 27 Philadelphia, PA 19104 28 parry@pennmedicine.upenn.edu 29 30 31 Number of text pages: 27 Tables: 6 32 33 Figures: 0 34 Short title: Placental pathology in COVID-19 cases 35

Abstract

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

The relationship among timing and severity of COVID-19 during pregnancy, placental pathology, and adverse pregnancy outcomes is not well understood. We conducted a prospective cohort study of 497 pregnant patients with COVID-19 whose placentas underwent systematic pathologic examination. The main exposure was timing of COVID-19 during pregnancy (first or second versus third trimester). The primary outcome was composite placental pathology that included high grade maternal vascular malperfusion or greater than 25 percent perivillous fibrin deposition. There were 63 patients who had the composite placental pathology outcome. In adjusted analyses that controlled for maternal age, parity, active infection at delivery, interval from time of diagnosis to delivery and COVID-19 variant, timing of COVID-19 during pregnancy was not associated with risk of the composite placental pathology outcome. Among secondary COVID-19 related exposures we investigated, severity of disease and treatment for COVID-19 were associated with risk of the composite placental pathology outcome. In addition, patients with COVID-19 in the first nine months of the pandemic had the highest rate of the composite placental pathology outcome. In this large cohort, placental vascular pathology was common among COVID-19 cases but was unrelated to timing of COVID-19 during pregnancy or adverse pregnancy outcomes. These findings suggest that uncomplicated COVID-19 during pregnancy does not require intensive fetal surveillance or detailed pathologic examination of the placenta after delivery.

Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Pregnancy appears to be a risk factor for severe disease with 2019 novel coronavirus disease (COVID-19). Immediately following the start of the pandemic case studies were published reporting the increased incidence of maternal morbidity and mortality and adverse pregnancy outcomes. We now have a better understanding of the increased risk of adverse outcomes following COVID-19 during pregnancy. 1-4 Smith et al. recently published a meta-analysis that included over 13,000 pregnancies included in 12 studies across 12 countries.3 They found a significantly greater risk of mortality, admission to intensive care unit, and other morbidities among pregnant patients with COVID-19. They also found an increase in preterm birth and low birth weight if the neonate was born to a patient with severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection during pregnancy. Many other reports associate COVID-19 with adverse pregnancy outcomes, including fetal growth restriction, hypertensive disorders of pregnancy, and fetal loss. 3,5-7 Most of these adverse pregnancy outcomes are attributed to placental dysfunction, 8-12 but the effects of COVID-19 on placental pathology and placental function have not been fully elucidated. 13-17 Placental pathology frequently is reported in pregnancies complicated by maternal SARS-CoV-2 infection. Vasculopathies and inflammation have been reported commonly in case series and small cohort studies. 13,14,17-21 Corbetta-Rastelli et al. recently conducted a relatively large cohort study that included 138 placentas with infections during pregnancy.²² Similar to many smaller studies published previously, they found a high incidence of maternal vascular malperfusion. Unlike previous studies, this study evaluated the placenta following resolved SARS-CoV-2 infection. Interestingly, they found that placentas from pregnancies with resolved and active infection had maternal vascular malperfusion. They also tested for a specific pathological feature dependent on the gestational timing of infection, but did not find one. However, they did

report a higher frequency of placental pathology findings if the infection occurred before 20 weeks of gestation.²²

This study aimed to identify factors contributing to the development of placenta pathology following SARS-CoV-2 infection. We hypothesized that COVID-19 causes pathologic changes in the placenta that are not related to timing or severity of clinical disease. To test this hypothesis, we assembled a large cohort of patients diagnosed with COVID-19 during pregnancy whose placentas underwent comprehensive pathologic examination performed by an experienced placental pathologist blinded to demographics and outcomes data for each patient. Our study population includes patients of diverse racial and ethnic backgrounds, various gestational timing of infection, and a range of COVID-19 severity. The primary outcome we studied was a composite of placental pathology findings (high grade maternal vascular malperfusion (MVM) and/or presence of greater than 25 percent perivillous fibrin deposition), and exposures we compared included timing of infection during pregnancy (first or second trimester versus third trimester), severity of COVID-19, and SARS-CoV-2 variants (four time periods of the COVID-19 pandemic). Secondary outcomes included adverse pregnancy outcomes stratified by presence or absence of placental pathology.

Methods

This study was carried out with Institutional Review Board approval (protocol #843277) using clinical and pathologic material collected from the Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania.

Selection of subjects

Women with a history of SARS-CoV-2 infection during pregnancy were identified either prospectively by a clinician/research coordinator present on the Labor and Delivery unit or

retrospectively by searching the HUP pathology database for placentas with the clinical history of "COVID-19", "COVID-19 positive", "SARS-CoV-2", "SARS-CoV-2 positive", and "resolved COVID-19" from March 1, 2020 to February 28, 2022. During the study period, universal screening via nasopharyngeal polymerase chain reaction (PCR) for SARS-CoV-2 was performed for all admissions to the labor and delivery unit at our institution. The placentas of all patients with a positive SARS-CoV-2 test or a self-reported history of infection during pregnancy were sent for routine gross and microscopic pathologic examination. COVID-19 cases for this study were selected from this population based on the following criteria: singleton delivery at or after 28 weeks gestational age (third trimester), and a documented positive SARS-CoV-2 PCR test during pregnancy. Additionally, cases with fetal congenital or genetic anomalies or a known non-SARS-CoV-2 viral infection during this pregnancy (e.g., HIV, CMV, etc.) were excluded. In order to compare rates of placenta pathology between COVID-19 cases and healthy controls, we submitted placentas from a small group of healthy controls (N=26) who delivered during the same time period for routine gross and microscopic pathologic examination.

Clinical and demographic data collection

Maternal clinical characteristics were extracted from electronic medical records including maternal age at delivery, gravidity, parity, race/ethnicity, pre-gravid body mass index (kg/m²), history of maternal disease (e.g. chronic hypertension, gestational hypertension, preeclampsia, pre-gestational diabetes, or gestational diabetes), and maternal use of aspirin during pregnancy. Obstetrical and neonatal outcomes that we studied included gestational age at delivery (weeks), preterm birth (before/after 37 weeks), birthweight, fetal sex, gestational hypertension, severe maternal morbidity, ²³ and severe neonatal morbidity. ^{24,25} Birthweight z-scores were calculated using research calculator references and standardized by both gestational age and newborn sex. ^{26,27} In accordance with the American College of Obstetricians and Gynecologists definition of severe maternal morbidity, ²³ the composite severe maternal morbidity outcome was defined

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

as any (or multiple) of the following: (1) acute respiratory distress syndrome: (2) acute myocardial infarction; (3) amniotic fluid embolism; (4) congestive heart failure; (5) sepsis/shock; (6) hemorrhage: (7) eclampsia: (8) disseminated intravascular coagulation: (9) hysterectomy: (10) ICU admission; (11) acute renal failure; (12) assisted ventilation (intubation); and (13) death. There were no maternal deaths. In accordance with the Maternal-Fetal Medicine Units Network criteria for severe neonatal morbidity. 24,25 the composite severe neonatal morbidity outcome was defined as any (or multiple) of the following: (1) respiratory distress syndrome; (2) transient tachypnea of the newborn: (3) sepsis: (4) assisted ventilation: (5) seizure: (6) grade 3 or 4 intraventricular hemorrhage; (7) necrotizing enterocolitis; (8) NICU admission; and (9) CPAP or supplemental oxygen. The severity of maternal COVID19 disease was categorized based on National Institutes of Health and Society for Maternal-Fetal Medicine criteria initially issued in 2020: 1 - Asymptomatic Infection: Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic test but have no symptoms. 2 - Mild Illness: Individuals who have any of the various signs and symptoms of COVID 19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging. 3 - Moderate Illness: Individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO₂) ≥94% on room air at sea level. 4 - Severe Illness: Individuals who have respiratory frequency >30 breaths per minute, SpO₂ <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) <300 mmHg, or lung infiltrates >50% 5 - Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

The gestational age at the time of positive SARS-CoV-2 test was collected and the days from diagnosis to delivery were calculated. Maternal COVID-19 status at delivery was further categorized as active (positive test result at the time or within 14 days of delivery) or resolved (positive test result > 14 days before date of delivery). Infants delivered to patients with active COVID-19 at the time of delivery were routinely tested via nasopharyngeal swab PCR test for SARS-CoV-2 at 24 and 48 hours of life. If an infant was tested for SARS-CoV-2 after delivery, these results were also collected. A publicly available surveillance sequencing dashboard of SARS-CoV-2 variants circulating in the Philadelphia region since March 2020 was utilized to categorize patients into one of four variant time periods (City of Philadelphia Department of Public Health, (https://microb120.med.upenn.edu/data/SARS-CoV-2/). As our institution is one of the main contributors to this dashboard and a majority of patient's delivering at our institution are located within the geographic region covered by this collaborative effort, these data should represent our patient population. Based on the predominant variants present, patients were categorized based on the date of their positive SARS-CoV-2 PCR test as follows: Pre-variants of COVID-19 (pVOC): March 2020 – December 2020 Alpha: January 2021 - May 2021 June 2021 – December 2021 Delta: Omicron: January 2022 – February 2022 Placenta pathologic data collection All placentas were examined in the pathology department at HUP utilizing a systematic protocol, including recording the trimmed placental weight, membrane insertion site, gross appearance. dimensions of the placental disc, and the insertion, length, and diameter of the umbilical cord.

Histologic samples included sections of membranes, umbilical cord, and at least three full-thickness sections of non-lesion placental parenchyma. The placentas from COVID-19 cases were fixed in 10% buffered formalin for at least 24 hours prior to examination. Macroscopic and microscopic lesions were described primarily according to the Amsterdam Placental Workshop Group 2014 classification and further defined as per **Table 1**. 28-30 A composite of high grade MVM and/or presence of greater than 25 percent perivillous fibrin deposition was the primary placental pathology outcome we investigated. Microscopic examination was performed by a single perinatal pathologist for all placentas (R.L.L.) blinded to exposures (i.e., timing and severity of COVID-19) and clinical outcomes. Subsequently, a second review on a subset of 32 placentas was performed to assess inter-observer reliability. Slides were reviewed independently by two pathologists (R.L.L. and J.C.G.) to assess for the presence or absence of: chronic inflammation including chronic villitis and chronic histiocytic intervillositis; fetal vascular malperfusion (FVM) including fetal vascular thrombi, avascular villi and villous stromal vascular karyorrhexis; MVM including decidual vasculopathy, villous infarction, accelerated villous maturation, distal villous hypoplasia; and increased perivillous fibrin deposition.

Statistical Analysis

Statistical analyses were performed with SAS 9.4 for Windows. An alpha level of 0.05 was used to determine statistical significance; Bonferroni correction was used for multiple comparisons.

Timing of COVID-19 during pregnancy (first or second trimester versus third trimester) was the main exposure and a composite of placental pathology, defined as the presence of high grade MVM and/or presence of greater than 25 percent perivillous fibrin deposition, was the primary outcome.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

Patient demographics included maternal age (years): race (Black/African American versus Caucasian/Asian/Other); gestational age (weeks); fetal sex (male versus female); chronic hypertension; diabetes; active infection at delivery; COVID-19 treatment; COVID-19 vaccination preceding COVID-19 diagnosis; COVID-19 severity (asymptomatic/mild versus moderate/severe/critical); COVID-19 variant (pVOC/alpha/delta/omicron); and infection exposure window (days from delivery). Summary statistics were computed as frequencies and proportions for all categorical variables. Maternal age and exposure window were summarized with mean and standard deviation. Chi-square test for independence, Student's t-test, and Wilcoxon ranked sum test were performed to examine bivariable associations between timing of exposure and patient characteristics. All characteristics with P<0.05 were considered potential confounders and included in an adjusted logistic regression model. Simple logistic regression was first performed to find the crude association between timing of COVID-19 during pregnancy (first or second trimester versus third trimester) and the composite placental pathology outcome. Next, potential confounding variables were placed in a regression model for adjusted estimates of the association between timing of infection and odds of the composite placental pathology outcome. Results A total of 497 placentas from patients who had COVID-19 during pregnancy were evaluated for this study. Within this cohort, 156 patients had COVID-19 during the first or second trimester and 341 patients had COVID-19 during the third trimester (primary exposure). Sixty-three patients had the composite placental pathology outcome (high grade MVM and/or presence of greater than 25 percent perivillous fibrin deposition), and 434 did not have the primary outcome.

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

Demographic characteristics and secondary COVID-19 related exposures were compared between patients with COVID-19 in the first or second trimester versus patients with COVID-19 in the third trimester (timing of COVID-19 during pregnancy, primary exposure of interest, **Table** 2). Among the demographic characteristics we studied, maternal age was greater and patients were more likely to be multiparous among the group with COVID-19 in the first or second trimester. In accordance with study design, COVID-19 at delivery was less common and the interval from COVID-19 diagnosis to delivery was greater among the group with COVID-19 in the first or second trimester. In unadjusted analyses, timing of COVID-19 during pregnancy was not associated with increased risk of the composite placental pathology outcome – 22/156 (14.1 percent) patients with COVID-19 in the first or second trimester compared to 41/341 (12.0 percent) with COVID-19 in the third trimester (P=0.518, OR 1.20, 95 percent CI 0.69, 2.10; **Table 3**). Maternal age, parity, active infection at delivery, interval from time of diagnosis to delivery, and COVID-19 variant were associated with the primary exposure, trimester of infection (Table 2). Hence, in adjusted analyses, we controlled for these variables and determined timing of COVID-19 during pregnancy was not associated with odds of composite placental pathology in this sample (P=0.547, OR 1.33, 95 percent CI 0.53, 3.34). Among the secondary COVID-19 related exposures we investigated, severity of disease (moderate/severe/critical versus asymptomatic/mild) and treatment for COVID-19 (yes/no) were associated with risk of the composite placental pathology outcome (P<0.05), while COVID-19 vaccination (yes/no) and COVID-19 active at delivery (yes/no positive SARS-CoV-2 PCR at

delivery admission) were not associated with the composite placental pathology outcome.

Although there were not statistically different rates of the composite placental pathology outcome among the four SARS-CoV-2 variants (P=0.070, **Table 3**), we did observe a trend

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

toward greater rates of the composite placental pathology outcome in the earlier epochs during the pandemic – pVOC (March 2020 – December 2020, 18.2 percent), Alpha (January 2021 – May 2021, 10.5 percent), Delta (June 2021 – December 2021, 12.6 percent), Omicron (January 2022 - February 2022, 7.3 percent). After correcting for multiple comparisons (Bonferroni significance = 0.008 for analysis of six secondary outcomes), no secondary obstetrical/neonatal outcomes were associated with timing of COVID-19 during pregnancy (**Table 4**). In stratified analyses, we found that timing of COVID-19 during pregnancy in patients with the composite placental pathology was not associated with risk of secondary maternal/neonatal outcomes, while timing of COVID-19 during pregnancy in patients without the composite placental pathology was associated with risk of spontaneous preterm birth (15/134 [11.2 percent] patients with COVID-19 in the first or second trimester versus 12/300 [4.0 percent] patients with COVID-19 in the third trimester; P=0.004, **Table 5**). Timing of COVID-19 during pregnancy and secondary COVID-19 exposures were not associated with other individual placental pathology outcomes that we investigated (Table 6. P>0.05 for all outcomes). In order to compare rates of placenta pathology between COVID-19 cases and healthy controls, we analyzed placentas from a small group of healthy controls (N=26) who delivered during the same time period (March 1, 2020 to February 28, 2022). Although low grade MVM or FVM was observed in 7/26 controls (26.9 percent), none of the placentas from 26 healthy controls had the composite placental pathology outcome (high grade MVM or presence of greater than 25 percent perivillous fibrin deposition). The previously collected data were not changed by the results of our interobserver reliability assessment. Interobserver agreement between the two pathologists ranged from substantial to

almost perfect for the two components of the composite placental pathology outcome: kappa = 0.761 for >25 percent perivillous fibrin deposition, kappa = 0.930 for high grade MVM.³¹

Discussion

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

In this large cohort, the composite placental pathology outcome (high grade MVM or presence of greater than 25 percent perivillous fibrin deposition) was relatively common among COVID-19 cases but was unrelated to timing of COVID-19 during pregnancy (first or second trimester versus third trimester) and adverse pregnancy outcomes. Among the secondary COVID-19 related exposures we investigated, severity of disease (moderate/severe/critical versus asymptomatic/mild) and treatment for COVID-19 (yes/no) were associated with risk of the composite placental pathology outcome. Spontaneous preterm birth occurred more frequently among patients with COVID-19 in the first or second trimester compared to COVID-19 in the third trimester, but in stratified analyses, we discovered that increased rates of spontaneous preterm births were restricted to patients with COVID-19 in the first or second trimester who did not have the composite placental pathology. An interesting trend we observed is that the composite placental pathology outcome occurred most frequently among pregnant patients who had COVID-19 early in the pandemic: March – December 2020 (pre-variants of COVID-19, 25/137, 18.2 percent) versus January – February 2022 (Omicron, 8/110, 7.3 percent). Early reports during the COVID-19 pandemic showed low rates of placental infection with SARS-CoV-2 but high rates of placental pathology, including MVM, FVM, and villitis of unknown origin.¹³⁻¹⁷ A later meta-analysis that included 56 studies and pathological examination of 1,008 placentas from patients who had COVID-19 largely at the time of delivery revealed rates of MVM, FVM, and perivillous fibrin deposition that ranged from 25 to 33 percent, and these rates were higher in cases compared to healthy controls who did not have COVID-19 during pregnancy. 32 Placental pathology is extensive in pregnancies complicated by acute SARS-CoV-

2 infection, although less is known about placental pathology following a resolved infection during pregnancy. Here we report similar placental pathology in pregnancies with a resolved SARS-CoV-2 infection, even months after infection. This confirms the previous report by Corbetta-Rastelli et al in a smaller cohort.²²

While asymptomatic infections cause placental pathology, it has previously been reported that pathology is independent of severity of disease.³² This conclusion is limited by the small cohorts reported thus far. In our cohort, we discovered that patients with a moderate, severe, or critical clinical presentation have a higher incidence of the composite placental pathology outcome than patients with an asymptomatic or mild case. We propose the difference between our study and others is due to the large sample size and assessment by the same team of pathologists.

Placental pathology is not correlated with adverse pregnancy outcomes. Other investigators studying COVID-19 in Philadelphia found a lack of correlation between preterm birth and placental pathology and suggested placental pathology and preterm birth are caused by divergent pathways.³³ We found that the risk of preterm birth is highest in COVID-19 patients without the composite placental pathology. These investigators also reported higher rates of placental vascular pathology in patients with COVID-19 but not a COVID-19 vaccine during pregnancy compared to controls.³³ We found a trend toward higher rates of the composite placenta pathology in patients who did not receive the COVID-19 vaccine compared to patients who did receive the COVID-19 vaccine (P=0.144), but the unvaccinated cases probably occurred earlier in the pandemic when the composite placental pathology outcome was observed most frequently.

The most recent studies of placental pathology in COVID-19 cases demonstrate high rates of placental pathology, and these investigators recommend that COVID-19 is a risk factor that requires close monitoring during pregnancy. Our data do not support these recommendations. We found that the composite placental pathology was unrelated to adverse pregnancy outcomes, and patients with COVID-19 early in pregnancy did not have higher rates of small for gestational age neonates (birthweight <10th percentile), preterm birth, the composite neonatal outcome, gestational hypertension, or severe maternal morbidity compared to patients with COVID-19 during the third trimester. Hence, we do not believe that uncomplicated COVID-19 during pregnancy requires intensive fetal surveillance or detailed pathological examination of placentas after delivery.

The reasons for high-rates of placental pathology in COVID-19 cases (63/497 [12.7 percent] in our cohort had high grade MVM or presence of greater than 25 percent perivillous fibrin deposition) remain poorly understood. COVID-19 induces systemic pro-inflammatory and procoagulant effects, so future work may focus on inflammatory mediators and coagulation factors that affect the placenta in COVID-19 cases.

Our study had several notable strengths and limitations. We believe this is the largest single center cohort of COVID-19 cases during pregnancy in which placental pathology was examined in detail. The study population is representative of COVID-19 cases in large medical centers that employed universal SARS-CoV-2 screening for patients admitted to labor and delivery units during the pandemic, and careful clinical phenotyping was performed. The primary pathologist was blinded to COVID-19 factors (i.e., timing and severity of disease) and pregnancy outcomes. Unfortunately, the study was limited by the small number of unaffected control placentas that were evaluated during the pandemic, because placentas from healthy patients with normal pregnancy outcomes are not routinely sent to pathologists for evaluation. In addition, the

primary exposure we evaluated (COVID-19 during the first or second trimester) occurred in only 156 of the total 497 patients within the overall cohort.

We conclude that placental vascular abnormalities occur in a large number of COVID-19 cases but do not appear to be related to timing of COVID-19 during pregnancy. However, COVID-19 severity and maternal race influence the incidence of placental pathology. In stratified analyses among patients with COVID-19 early in pregnancy, the composite placental pathology outcome was not associated with higher rates of severe maternal morbidity or the composite adverse neonatal outcome. Hence, we do not believe that intensive fetal surveillance (i.e., serial non-stress tests or biophysical profiles) and detailed examination of placental pathology are warranted in otherwise uncomplicated cases of COVID-19 during pregnancy. Additional research is needed to understand why these high rates of placental vascular abnormalities occur in COVID-19 cases.

References

- 1. Brandt JS, Hill J, Reddy A, et al. Epidemiology of coronavirus disease 2019 in
- pregnancy: risk factors and associations with adverse maternal and neonatal outcomes.
- 381 Am J Obstet Gynecol 2020.
- 382 2. Rasmussen SA, Jamieson DJ. COVID-19 and Pregnancy. Infect Dis Clin North Am
- 383 2022;36:423-33.
- 384 3. Smith ER, Oakley E, Grandner GW, et al. Adverse maternal, fetal, and newborn
- outcomes among pregnant women with SARS-CoV-2 infection: an individual participant
- data meta-analysis. BMJ Glob Health 2023;8.
- 387 4. Smith ER, Oakley E, Grandner GW, et al. Clinical risk factors of adverse outcomes
- among women with COVID-19 in the pregnancy and postpartum period: a sequential,
- prospective meta-analysis. Am J Obstet Gynecol 2023;228:161-77.
- 390 5. Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of
- 391 preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol
- 392 2022;226:68-89 e3.
- 393 6. Kazemi SN, Hajikhani B, Didar H, et al. COVID-19 and cause of pregnancy loss during
- the pandemic: A systematic review. PLoS One 2021;16:e0255994.
- 395 7. Metz TD, Clifton RG, Hughes BL, et al. Disease Severity and Perinatal Outcomes of
- 396 Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol
- 397 2021;137:571-80.
- 398 8. Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed:
- from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol
- 400 2019;221:437-56.
- 401 9. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of
- placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic
- pregnancies. Br J Obstet Gynaecol 1994;101:669-74.

- 404 10. Parry S, Sciscione A, Haas DM, et al. Role of early second-trimester uterine artery
- Doppler screening to predict small-for-gestational-age babies in nulliparous women. Am
- 406 J Obstet Gynecol 2017;217:594 e1- e10.
- 407 11. Reddy UM. Prediction and prevention of recurrent stillbirth. Obstet Gynecol
- 408 2007;110:1151-64.
- 409 12. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science
- 410 2005;308:1592-4.
- 411 13. Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers: Preliminary
- 412 Findings. Pediatr Dev Pathol 2020;23:177-80.
- 413 14. Cribiu FM, Erra R, Pugni L, et al. Severe SARS-CoV-2 placenta infection can impact
- 414 neonatal outcome in the absence of vertical transmission. J Clin Invest 2021.
- 415 15. Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. A mechanistic analysis placental
- intravascular thrombus formation in COVID-19 patients. Ann Diagn Pathol
- 417 2020;46:151529.
- 418 16. Patberg ET, Adams T, Rekawek P, et al. Coronavirus disease 2019 infection and
- 419 placental histopathology in women delivering at term. Am J Obstet Gynecol 2020.
- 420 17. Sharps MC, Hayes DJL, Lee S, et al. A structured review of placental morphology and
- 421 histopathological lesions associated with SARS-CoV-2 infection. Placenta 2020;101:13-
- 422 29.
- 423 18. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology
- 424 in COVID-19. Am J Clin Pathol 2020;154:23-32.
- 425 19. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe
- 426 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy:
- Measures of Immunity and Placental Histopathology. Obstet Gynecol 2021;138:281-3.
- 428 20. Wong YP, Khong TY, Tan GC. The Effects of COVID-19 on Placenta and Pregnancy:
- What Do We Know So Far? Diagnostics (Basel) 2021;11.

- 430 21. Joshi B. Chandi A. Srinivasan R. et al. The placental pathology in Coronavirus disease 431 2019 infected mothers and its impact on pregnancy outcome. Placenta 2022;127:1-7. 22. Corbetta-Rastelli CM, Altendahl M, Gasper C, Goldstein JD, Afshar Y, Gaw SL. Analysis 432 of placental pathology after COVID-19 by timing and severity of infection. Am J Obstet 433 434 Gynecol MFM 2023:5:100981. American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal 23. 435 Medicine, Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and review. Am 436 J Obstet Gynecol 2016;215:B17-22. 437 438 24. Chauhan SP, Rice MM, Grobman WA, et al. Neonatal Morbidity of Small- and Large-for-Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. Obstet Gynecol 439 2017;130:511-9. 440 441 25. Manuck TA, Rice MM, Bailit JL, et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. Am J Obstet Gynecol 2016;215:103 e1- e14. 442 26. Chou JH, Roumiantsev S, Singh R. PediTools Electronic Growth Chart Calculators: 443
- 444 Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res
- 445 2020;22:e16204.
- Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013;13:59.
- Freedman AA, Keenan-Devlin LS, Borders A, Miller GE, Ernst LM. Formulating a
 Meaningful and Comprehensive Placental Phenotypic Classification. Pediatr Dev Pathol
 2021;24:337-50.
- 451 29. Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions:
- Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med
- 453 2016;140:698-713.

454 30. Redline RW. Ravishankar S. Bagby CM. Saab ST. Zarei S. Four major patterns of 455 placental injury: a stepwise guide for understanding and implementing the 2016 Amsterdam consensus. Mod Pathol 2021;34:1074-92. 456 31. Sierra F, Cardenas A. Evidence-based medicine (EBM) in practice: agreement between 457 458 observers rating esophageal varices: how to cope with chance? Am J Gastroenterol 2007;102:2363-6. 459 32. Di Girolamo R, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-460 2 infection in pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol 461 462 MFM 2021;3:100468. 33. Boelig RC, Aghai ZH, Chaudhury S, Kazan AS, Chan JSY, Bergmann-Leitner E. Impact 463 of COVID-19 disease and COVID-19 vaccination on maternal or fetal inflammatory 464 response, placental pathology, and perinatal outcomes. Am J Obstet Gynecol 465 2022;227:652-6. 466 34. Milot C, Koch A, Averous G, Mayeur S, Deruelle P. Development of placental lesions 467 after recovery from COVID-19 during pregnancy: case-control study. BJOG 468 2023;130:949-58. 469 470 35. Montans Araujo J. Suy Franch A. Garcia Ruiz I. Maiz N. Garcia Aguilar E. Hidalgo Bermejo FJ. Impact of COVID-19 disease on placental histopathology. PLAXAVID study. 471 Histol Histopathol 2023:18639. 472 473

Table 1. Macroscopic and microscopic placental lesions (Amsterdam Placental Workshop Group 2014 classification).²⁴ A composite of high grade maternal vascular malperfusion (MVM) or presence of greater than 25 percent perivillous fibrin deposition was the primary placental pathology outcome we analyzed.

Variable	Lesions included	Definition of grading
Chronic inflammation	Membranes/chorionic plate: chronic chorionitis, chronic amnionitis Basal plate: chronic deciduitis with plasma cells Villi: chronic villitis, intravillous plasma cells Intervillous space: chronic histiocytic intervillositis (≥2% involvement of intervillous space) Fetal: eosinophilic T-cell vasculitis	High-grade: >2 compartments with chronic inflammation Low-grade: 1 compartment with chronic inflammation None: no compartments with chronic inflammation ²³
Fetal vascular malperfusion (FVM)	Fetal vascular thrombi or intramural fibrin deposition in umbilical, chorionic, or stem villous vessel; at least 3 foci of avascular villi and/or villous stromal vascular karyorrhexis (≥3 villi/focus)	High grade: ≥2 fetal chorionic or stem villous vascular thrombi or a total of ≥45 avascular villi over 3 sections examined Low grade: any FVM lesions insufficient for a high-grade categorization None: no fetal vascular lesions ²⁴
Maternal vascular malperfusion (MVM)	Decidual vasculopathy: fibrinoid necrosis/acute atherosis, persistent muscularization of basal plate arterioles, mural hypertrophy of membrane arterioles, basal decidual vascular thrombus, chronic decidual perivasculitis Villous infarction Accelerated villous maturation including increased syncytial knots for gestational age Distal villous hypoplasia Changes consistent with retroplacental hemorrhage/hematoma	High grade: accelerated villous maturation and ≥1of the following: placental weight <10 th percentile, multiple villous infarcts, or distal villous hypoplasia Low grade: any MVM lesions insufficient for a high-grade categorization None: no MVM lesions ²⁵
Perivillous fibrin deposition	Increased perivillous fibrin in the intervillous space (more than expected for gestational age)	≥10% perivillous fibrin deposition ≥25% perivillous fibrin deposition

Table 2. Demographics and secondary COVID-19 exposures comparing patients with COVID-19 in the first or second trimester and patients with COVID-19 in the third trimester (primary exposure). Chi-square and Fisher's exact tests were used to find P-values for categorical variables. Student's t-test and Wilcoxon ranked sum tests were used to find P-values for continuous measures. pVOC = pre-variants of COVID-19.

Variable		First or Second Trimester COVID-19 (N=156)	Third Trimester COVID-19 (N=341)	P value
Maternal age (yr)	Mean (SD)	30.3 (5.92)	28.1 (6.26)	<0.001
Parity	Nulliparous Multiparous	50 (26.2%) 106 (34.6%)	141 (73.8%) 200 (65.4%)	0.048
Fetal sex	Male Female	84 (32.6%) 72 (30.1%)	174 (67.4%) 167 (69.9%)	0.559
Maternal race	Black/African Am White/Asian/other	104 (29.7%) 52 (36.9%)	246 (70.3%) 89 (63.1%)	0.123
Chronic hypertension	No Yes	139 (31.1%) 17 (34.0%)	308 (68.9%) 33 (66.0%)	0.675
Diabetes	No Yes	139 (31.1%) 17 (34.0%)	308 (68.9%) 33 (66.0%)	0.675
Obesity (BMI≥40)	No Yes	83 (29.0%) 70 (34.7%)	203 (71.0%) 132 (65.3%)	0.187
COVID-19 at delivery	No Yes	149 (53.6%) 7 (3.2%)	129 (46.4%) 212 (96.8%)	<0.001
Interval from diagnosis to delivery (days)	Mean (SD)	118.5 (52.8)	17.2 (22.7)	<0.001
Treatment for COVID-19	No Yes	143 (31.5%) 12 (28.6%)	311 (68.5%) 30 (71.4%)	0.695
COVID-19 severity	Asymptomatic/mild Mod/severe/critical	137 (30.5%) 17 (37.8%)	312 (69.5%) 28 (62.2%)	0.316
COVID-19 vaccination	No Yes	119 (30.4%) 37 (34.9%)	272 (69.6%) 69 (65.1%)	0.379
SARS-CoV-2 variant	pVOC Alpha Delta Omicron	59 (43.1%) 23 (30.3%) 57 (32.8%) 17 (15.5%)	78 (56.9%) 53 (69.7%) 117 (67.2%) 93 (84.5%)	<0.001

Table 3. Unadjusted analyses of rates of composite placental pathology (primary outcome) compared between primary and secondary exposure groups. Chi-square tests were used to find P values. pVOC = pre-variants of COVID-19.

Variable		Absence of composite placental pathology outcome (N=434)	Presence of composite placental pathology outcome (N=63)	P value
Timing of	1 st /2 nd trimester	134 (85.9%)	22 (14.1%)	0.518
COVID-19 COVID-19 at	3 rd trimester	300 (88.0%) 241 (86.7%)	41 (12.0%)	
delivery	Yes	193 (88.1%)	37 (13.3%) 26 (11.9%)	0.633
Treatment for COVID-19	No Yes	401 (88.3%) 32 (76.2%)	53 (11.7%) 10 (23.8%)	0.024
COVID-19 COVID-19 severity	Asymptomatic/mild Mod/severe/critical	397 (88.4%) 35 (77.8%)	52 (11.6%) 10 (22.2%)	0.040
SARS-CoV-2 variant	pVOC Alpha Delta Omicron	112 (81.8%) 68 (89.5%) 152 (87.4%) 102 (92.7%)	25 (18.2%) 8 (10.5%) 22 (12.6%) 8 (7.3%)	0.070
COVID-19 vaccination	No Yes	337 (86.2%) 97 (91.5%)	54 (13.8%) 9 (8.5%)	0.144

Table 4. Obstetrical and neonatal outcomes. SGA=small for gestational age (birthweight <10th percentile, birthweight z-scores were calculated using research calculator references and standardized by both gestational age and newborn sex;^{21,22} SPTB=spontaneous preterm birth; PTB=preterm birth. P values were calculated by chi-square test; Bonferroni significance = 0.008 for analysis of six secondary outcomes.

Outcome		First or Second Trimester COVID-19 (N=156)	Third Trimester COVID-19 (N=341)	P value
SGA	BW>10 th percentile	139 (90.8%)	287 (84.7%)	0.062
JOA	BW<10 th percentile	14 (8.2%)	52 (15.3%)	0.002
Composite neonatal	No	123 (78.8%)	274 (80.4%)	0.698
outcome	Yes	33 (21.2%)	67 (19.6%)	0.090
CDTD <27 wk	No	140 (89.7%)	326 (95.6%)	0.012
SPTB <37 wk	Yes	16 (10.3%)	15 (4.4%)	0.012
Medically indicated PTB <37 wk	No	137 (87.8%)	313 (91.8%)	0.161
	Yes	19 (12.2%)	28 (8.2%)	0.101
Gestational hypertension	No	121 (77.6%)	253 (74.2%)	0.419
	Yes	35 (22.4%)	88 (25.8%)	0.419
Severe maternal morbidity	No	146 (93.6%)	310 (90.9%)	0.313
	Yes	10 (6.4%)	31 (9.1%)	0.313

Table 5. Stratified analyses comparing risk of adverse pregnancy outcomes based on timing of COVID-19 during pregnancy (first or second trimester versus third trimester) in patients with or without the primary placental pathology outcome (high grade maternal vascular malperfusion (MVM) or presence of greater than 25 percent perivillous fibrin deposition). SGA=small for gestational age (birthweight <10th percentile, birthweight z-scores were calculated using research calculator references and standardized by both gestational age and newborn sex;^{21,22} SPTB=spontaneous preterm birth; PTB=preterm birth. P values were calculated by chi-square test or Fisher's exact test (if ≤5 samples in a cell).

Patients with primary placental pathology outcome (N=63)				
Outcome		First or Second Trimester COVID- 19 (N=22)	Third Trimester COVID-19 (N=41)	P value
SGA	BW>10 th percentile BW<10 th percentile	17 (77.3%) 5 (22.7%)	25 (61.0%) 16 (39.0%)	0.265
Composite neonatal outcome	No Yes	13 (59.1%) 9 (40.9%)	28 (68.3%) 13 (31.7%)	0.465
SPTB <37 wk	No Yes	21 (95.4%) 1 (4.6%)	38 (92.7%) 3 (7.3%)	1.000
Medically indicated PTB <37 wk	No Yes	14 (63.6%) 8 (36.4%)	33 (80.5%) 8 (19.5%)	0.143
Gestational hypertension	No Yes	14 (63.6%) 8 (36.4%)	26 (63.4%) 15 (36.6%)	0.986
Severe maternal morbidity	No Yes	20 (90.9%) 2 (9.1%)	35 (85.4%) 6 (14.6%)	0.702
Patients without primary placental pathology outcome (N=434)				
Outcome		First or Second Trimester COVID- 19 (N=134)	Third Trimester COVID-19 (N=300)	P value

204	BW>10th percentile	122 (93.1%)	262 (87.9%)	0.105
SGA	BW<10th percentile	9 (6.9%)	36 (12.1%)	0.105
Composite neonatal	No	110 (82.1%)	246 (82.0%)	0.982
outcome	Yes	24 (17.9%)	54 (18.%)	0.962
SPTB <37 wk	No	119 (88.8%)	288 (96.0%)	0.004
SPIB <37 WK	Yes	15 (11.2%)	12 (4.0%)	0.004
Medically indicated	No	123 (91.8%)	280 (93.3%)	0.564
PTB <37 wk	Yes	11 (8.2%)	20 (6.7%)	0.504
Gestational	No	107 (79.8%)	227 (75.7%)	0.339
hypertension	Yes	27 (20.2%)	73 (24.3%)	0.339
Severe maternal	No	126 (94.0%)	275 (91.7%)	0.391
morbidity	Yes	8 (6.0%)	25 (8.3%)	0.391

Table 6. Secondary placenta pathology outcomes.

511

Outcome	Exposure	Unadjusted P value	Bonferroni P value ¹
	Timing of COVID-19 (trimester)	0.580	1
High grade fotal vecesiler	COVID-19 at delivery	0.812	1
High grade fetal vascular malperfusion	Treatment for COVID-19	0.7518	1
maiperiusion	COVID-19 severity	0.180	0.901
	SARS-CoV-2 variant	0.186	0.932
	Timing of COVID-19 (trimester)	0.554	1
	COVID-19 at delivery	0.913	1
Fetal vascular thrombi	Treatment for COVID-19	0.453	1
	COVID-19 severity	0.784	1
	SARS-CoV-2 variant	0.342	1
	Timing of COVID-19 (trimester)	0.303	1
High grade obrania	COVID-19 at delivery	0.419	1
High grade chronic inflammation	Treatment for COVID-19	0.917	1
Illiaminauon	COVID-19 severity	0.100	0.501
	SARS-CoV-2 variant	0.898	1
	Timing of COVID-19 (trimester)	0.592	1
Chronic histiocytic	COVID-19 at delivery	0.196	0.982
intervillositis or high grade	Treatment for COVID-19	0.965	1
chronic villitis	COVID-19 severity	0.014	0.069
	SARS-CoV-2 variant	0.926	1

¹Bonferroni adjustment for five potential predictors to minimize chances of a Type 1 error.